Skip to Content

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

Many patients with advanced-stage lung cancer cannot tolerate standard platinum-based chemotherapy. As a late-breaking Siow Ming Lee presents the first randomized trial to show that first-line atezolizumab treatment significantly improves overall survival compared to single agent chemotherapy for these poor prognosis patients with no EGFR and ALK alterations.

Siow Ming Lee

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top